Basilea Pharmaceutica AG (LON:0QNA)

Market Cap	609.80M +21.0%
Revenue (ttm)	217.74M +11.4%
Net Income	37.71M -48.1%
EPS	2.94 -46.1%
Shares Out	n/a
PE Ratio	16.17
Forward PE	12.92
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,078
Average Volume	5,150
Open	50.80
Previous Close	52.33
Day's Range	50.50 - 52.50
52-Week Range	38.60 - 59.55
Beta	0.46
RSI	46.28
Earnings Date	Feb 17, 2026

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a cli...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2000
• Employees: 189
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QNA

Financial Performance

In 2025, Basilea Pharmaceutica AG's revenue was 232.38 million, an increase of 11.43% compared to the previous year's 208.54 million. Earnings were 40.24 million, a decrease of -48.14%.

Financial numbers in CHF